Search
for
Sort by
Community Join
30-60 / 1000+ resultscommunity Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Where can i buy Setipiprant from ? Does it work ? and are there any threads anyone could link so i could check it out and also suppliers? thanks
community Potentially Positive Pyrilutamide News Coming
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
community Cetirizine works
community Latanoprost, worth it?
community When is Kintor pyrilutamide (KX-826) expected to release phase 3 results and potentially be available to US consumers?
Kintor pyrilutamide (KX-826) phase 3 results are expected by the end of 2024 or early 2025. The China trial enrollment is complete.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community Fevipiprant 2019!
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Link to the conference for Kintor Pyrilutamide
User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.
community Want to add Pyrilutamide to My Topical Stack
community sublingual dutasteride to increase bioavailability?
community Alfatradiol and PG and RU58841
community Tap water fine to use for Topical cetirizine?
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
community is there value in using less topical dut while adding in Eucapil?
community Alternative DHT inhibitors when you can't tolerate Fin/Dut
community RU58841 premixed solution - got side effects - not sure what to do next
community What's better Ru or pyrilutamide
RU58841 is considered more effective but potentially riskier than pyrilutamide. The user plans to try pyrilutamide, believing it to be safer.
community The New, Improved CB-03-01/Setipiprant Group Buy
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
community Topical bicalutamide after fin/dut?
community KX-826 (Pyrilutamide) on Amazon
The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.
community How is the GT20029 different to pyrilutamide as an androgenic antagonist
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
community Upcoming Setipiprant clinical trials hint at systemic daily dosage
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.